Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Find out what positions HIMS as a key ...

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s stock price gapped up prior to trading on Monday after Canaccord Genuity Group raised their price target on the stock from $28.00 to $38.00.

Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...

Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a ...

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.15 which represents a slight increase of $1.81 or 5.97% from the prior close of $30.34. The stock opened at ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that Hims & ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Hims & Hers Health (HIMS) has soared after Hunterbrook Media says that the company could benefit from President-elect Donald ...

Hims & Hers ( HIMS -0.72%) announced this week that it's getting into the nutrition business with bars and shakes. But are ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic ...